Join 100+ monthly customers
If a clinic offers injectable GHK-Cu, BPC-157, or TB-500, that route depends on compounding rules, which were in flux in 2026, and is distinct from using an FDA-approved drug
Early studies on Gly-His-Lys (GHK), first discovered in human plasma in the 1970s, demonstrated their ability to modulate gene expression, stimulate collagen synthesis, and accelerate wound healing, sparking broad interest in these bioactive molecules [23]
For most people, 36 months is the sweet spot
For formulators, this creates opportunities to differentiate products based on genuine functional advantages rather than marketing claims alone
Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D